Micronized Palmitoylethanolamide, Hempseed Oil, and Maritime Pine Bark Dry Extract (Pelvipea®) for Pelvic Pain: An In Vitro Study for Urothelial Inflammation Treatment
Laboratory studyHumansWith hempseed oil and maritime pine bark dry extract (combined as Pelvipea)
This study tested palmitoylethanolamide together with hempseed oil and maritime pine bark dry extract (combined as Pelvipea). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- T24 human bladder urothelial cell line exposed to conditioned media from E. coli-stimulated THP-1 human macrophages
- Dose used in the study
- Micronised palmitoylethanolamide, hempseed oil and maritime pine bark dry extract tested individually and as a mixture (Pelvipea), at concentrations up to 230 micrograms/mL
- Duration
- Not stated in the abstract
- What was measured
- NF-kB transcription factor levels and pro-inflammatory cytokine (IL-1beta, IL-6, IL-8) expression in urothelial cells after an inflammatory stimulus.
What the authors reported
This in vitro study found:
- None of the ingredients reduced THP-1 cell viability.
- NF-kB was reduced by hempseed oil, pine bark extract and the mixture at all concentrations tested, and by micronised palmitoylethanolamide from 25 to 200 micrograms/mL.
- At 230 micrograms/mL the mixture gave the lowest IL-1beta, IL-6 and IL-8 levels of all conditions tested (fold-change 0.08, 0.01 and 0.32 respectively).
Limits of this study
An in vitro cell study; it cannot show effect on pelvic pain in people or animals. The authors declare no conflict of interest.
Source
PubMed 36831284 · doi:10.3390/cells12040616
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.